We followed 54 subjects with heterozygous familial hypercholesterolemia for an average of 10 (range 3-14) years. Half were treated surgically with partial ileal bypass and the other half (matched for age, sex, coronary heart disease, blood pressure, diabetes mellitus, smoking, obesity, and serum cholesterol concentration) were treated conservatively with diet and hypolipidemic drugs. The mean decrease in serum cholesterol concentration from the average value of 522 mg/dl on entry into the study was 32% in the surgically treated group and 10% in the conservatively treated group. One quarter of the subjects (14 of 54) had symptomatic cerebrovascular disorders and one tenth (six of 54) sufiFered a brain infarction at a mean age of 43 (range 30-57) years. Two thirds of the brain infarctions occurred during follow-up. The method of treatment of familial hypercholesterolemia did not affect the number of new cerebrovascular events. The incidence of brain infarction was 7.4/1000/yr. The risk of brain infarction in these subjects with familial hypercholesterolemia was at least 20 times higher than in the general population. We conclude that symptomatic subjects with familial hypercholesterolemia have not only a high risk of coronary heart disease but also a high risk of cerebrovascular disorders. (Stroke 1988;19:1097-1100) F amilial hypercholesterolemia (FH) is a hereditary metabolic disorder that causes premature atherosclerosis. 1 Ischemic heart disease is the major life-threatening complication of FH, but less is known about cerebrovascular disorders (CVD) in these patients 2 -4 even though atherosclerotic lesions are often detected in their extracranial carotid arteries. 56 We followed subjects with heterozygous FH for an average of 10 years to find out how often they suffer brain infarction (BI) and whether treatment of hypercholesterolemia affects the risk of ischemic BI.
F amilial hypercholesterolemia (FH) is a hered-
itary metabolic disorder that causes premature atherosclerosis. 1 Ischemic heart disease is the major life-threatening complication of FH, but less is known about cerebrovascular disorders (CVD) in these patients 2 -4 even though atherosclerotic lesions are often detected in their extracranial carotid arteries. 56 We followed subjects with heterozygous FH for an average of 10 years to find out how often they suffer brain infarction (BI) and whether treatment of hypercholesterolemia affects the risk of ischemic BI.
Subjects and Methods
We investigated 54 subjects (34 men and 20 women) with heterozygous FH. FH was diagnosed based on lipid profiles (serum cholesterol concentration of >368 mg/dl with normal or moderately elevated serum triglyceride concentration), tendon xanthomas, and family history. 7 The 54 subjects were drawn from people referred to the Lipid Clinic of the Helsinki University Central Hospital because of lipid abnormalities. The mean age of the subjects at entry into the study was 37 (range 21-50) years.
All 27 patients with FH (17 men and 10 women) who were treated surgically with partial ileal bypass 8 to reduce their serum cholesterol concentrations were entered into the study. The decision for surgery was made by the physician of the patient at the Lipid Clinic together with the patient.
Controls with FH matched with the 27 patients for age, sex, coronary heart disease (CHD), blood pressure, follow-up time, diabetes mellitus, smoking, obesity, and serum cholesterol concentration were selected from 230 hyperlipidemic people examined during the same period in the Lipid Clinic but treated conservatively. Conservative medical treatment consisted of diet and hypolipidemic drugs (clofibrate, cholestyramine, neomycin, and nicotinic acid).
We used only data collected at the first visit (defined as entry into the study) in matching the patients and controls, which was done before followup examination by a person not knowing the outcome of the subjects. The lipid concentrations at entry into the study were measured when the subjects had been at least 2 months without hypolipidemic drugs. Ten subjects (five patients and five controls) were taking /3-blockers and one female control was taking aspirin. No other subjects were taking antiplatelet or anticoagulant drugs.
The criteria for diagnosis of transient ischemic attack (TIA) and BI were those suggested by the Study Group on TIA Criteria and Detection 9 and The number of subjects with CHD, TIA, and ischemic BI on entry into the study are shown in Table 1 : 40 had CHD, 13 had arterial hypertension (defined as diastolic blood pressure of >95 mm Hg), one had diabetes mellitus, and 21 smoked. The prevalence of CHD (21 patients and 19 controls), hypertension (six patients and seven controls), and smokers (11 patients and 10 controls) was similar in both treatment groups. Only three subjects (two patients and one control) had symptomatic intermittent claudication.
Serum total cholesterol" and triglyceride 12 concentrations were measured using an Auto-Analyzer (Technicon Instruments Corporation, Tarrytown, New York). Lipoprotein cholesterol concentration was measured by an enzymatic method. 13 Very low density lipoprotein was separated by ultracentrifugation at d< 1.006 g/ml. Low density lipoprotein (LDL) and high density lipoprotein (HDL) were separated from the infranatant by the heparinmanganese method.
14 Apoprotein B (ApoB) was measured by immunodiffusion (M-Partigen, Behringwerke AG, Marburg, FRG). Apoprotein A-I (ApoAI) was measured by immunoturbidometry 15 using monospecific antisera (Boehringer Mannheim Gmbh, Mannheim, FRG). The mean±SD lipid concentrations on entry into the study according to disorders and treatment are shown in Table 2 .
The subjects were followed in the Lipid Clinic at 3-12-month intervals. We reexamined the subjects after a mean of 10 (range 3-14) years. The case records, death certificates, and autopsy records of the 10 men (five patients and five controls) who died during follow-up were reviewed. 
Results
Neither serum cholesterol concentration nor age of the subject on entry into the study correlated with the risk of CVD. Serum cholesterol concentrations on entry into the study did not differ among subjects with CHD, CVD, both, or neither. Subjects with CVD only had slightly higher serum triglyceride concentrations than those with CHD only and those with neither CHD nor CVD, but the differences were not significant ( Table 2) .
During follow-up there were four TIAs, four ischemic Bis, and one retinal infarction (Table 3) . There was a total of 10 TIAs. The mean age at the time of TIA was 39 (range 21-50) years. TIAs comprised three cases of amaurosis fugax, five hemispheric TIAs, and two vertebrobasilar TIAs. There was a total of six Bis. The mean age at the Patients treated with partial ileal bypass; controls treated with diet and hypolipidemic drugs. CHD, coronary heart disease; fatal CHD, myocardial infarction or sudden coronary death; MI, myocardial infarction; CVD, cerebrovascular disorders; TIA, transient ischemic attack. Data are mean±SD mg/dl. HDL, high density lipoprotein; LDL, low density lipoprotein; patients treated with partial ileal bypass; controls treated with diet and hypolipidemic drugs; CHD, coronary heart disease; CVD, cerebrovascular disorders.
time of BI was 43 (range 30-57) years. Five Bis were hemispheric and one was vertebrobasilar. One patient suffered a retinal infarction at the age of 56 years. Altogether, 14 subjects had TIA, BI, and/or retinal infarction. The incidence of ischemic BI was 7.4/1000/yr during follow-up. Ten subjects died during follow-up, nine of CHD and one male control of malignancy.
Overall mean ± SD serum cholesterol concentrations decreased 20.6 ±19.2% during follow-up. A decrease of 31.5 ± 12.0% was observed among the patients, but the decrease was only 10.1 ±18.6% among the controls (p<0.001).
The decrease in serum cholesterol concentration in surviving subjects did not differ among those who suffered new CHD, CVD, or neither CHD nor CVD events during follow-up. A decrease of >30% was chosen to indicate a good response to treatment. Such a decrease was achieved in 17 surviving subjects (14 patients, three controls), while in 27 (eight patients, 19 controls) the decrease was smaller. One good responder and three poor responders suffered BI during follow-up. One good responder (a patient) suffered retinal infarction.
At the end of the study the mean serum concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, ApoAI, or ApoB in surviving subjects did not differ according to CHD, CVD, or the absence of both (Table 4) .
Discussion
Information about CVD in subjects with heterozygous FH is scanty, 2 -4 and no information is available about their incidence of ischemic BI. Our main objective was to evaluate the incidence of BI in subjects with heterozygous FH.
One quarter of our subjects (14 of 54) had symptomatic CVD (TIA, amaurosis fugax, BI, or retinal infarction) and one tenth (six of 54) suffered a BI when events before and during follow-up were combined. In earlier studies the prevalence of CVD has varied from 1.2% to >50% in patients with FH. 317 In one study 17 most patients had vertebrobasilar TIAs, and the diagnostic criteria for TIAs were not as strict as those suggested by the Study Group on TIA Criteria and Detection, 9 which we used. The prevalence of BI in our subjects tallies with the prevalence of CVD in patients with FH described by De Gennes and coworkers. 4 The incidence of BI was 7.4/1000/yr in our study. This is high and emphasizes that subjects with heterozygous FH have a high risk not only of CHD but also of BI. The mean age of our subjects at the time of BI was 43 years. In the general population of the Helsinki metropolitan area, the annual stroke incidence in the group aged 35-44 years is 0.38/ 1000; furthermore, that figure includes not only BI but all kinds of strokes. 18 Accordingly, the risk of BI in our subjects with FH is at least 20 times higher than that in the general population. This tallies with the 25 times increased risk of CHD in FH patients compared with their unaffected relatives in the study by Patterson and Slack. 19 Our study demonstrates that CVD develops concurrently with CHD in a significant proportion of subjects with heterozygous FH although symptomatic CHD preceded CVD events in most subjects. The high incidence of BI in our subjects may not be applicable to all those with FH. More than two thirds of our subjects had CHD, which tallies with earlier observations.2.20,21 This j S ; however, twice the prevalence of CHD in FH patients of the same age found by Stone et al, 22 who studied the relatives of affected propositi. The same may also hold true for the risk of BI.
In our subjects the severity of lipid abnormalities or their age did not correlate with CVD, although these parameters have been shown to correlate with extracranial carotid atherosclerosis in patients with FH. 5 In our subjects, however, lipid abnormalities were much more severe than in the patients studied by Postiglione and coworkers. medical therapy on the risk of CVD. A good response to hypolipidemic therapy has been associated with a benign course of extracranial carotid artery disease in patients with FH. 6 In spite of the overall mean 21% decrease in serum cholesterol concentration, our subjects suffered four TIAs, four ischemic Bis, and one retinal infarction during follow-up. A mean decrease of 32% was achieved by surgical therapy compared with a mean decrease of 10% with conservative medical therapy, but the method of treatment of FH did not affect the number of new cerebrovascular events.
Our results differ from those achieved with colestipol and nicotinic acid with which TIA and amaurosis fugax ceased and no patient suffered BI or retinal infarction. 6 The difference may have many explanations. First, the mean serum cholesterol concentration on entry into our study was clearly higher (522 mg/dl in our study and 378 mg/dl in the series of Kuo and coworkers 6 ). Even after treatment the mean serum cholesterol concentration in our subjects remained higher than that before treatment in the patients of Kuo and coworkers. 6 Second, in the study of Kuo et al 6 the mean decrease in serum cholesterol concentration was 42%, while in our subjects it was only 21%. Third, we followed our subjects for an average of 10 years, while the followup was 4-5 Vi years in the series of Kuo et al. 6 We conclude that the risk of ischemic BI in subjects with heterozygous FH is 7.4/1000/yr, at least 20 times higher than that in the general population. Neither surgical nor conservative medical treatment of FH eliminated the risk of BI at a relatively young age in our subjects.
